COVID-19: известные препараты, новые возможности

COVID-19: известные препараты, новые возможности

Автор: Аширметов А.Х., Мавлянов И.Р., Мавлянов З.И., Жарылкасынова Г.Ж.

Журнал: Анализ риска здоровью @journal-fcrisk

Рубрика: Аналитические обзоры

Статья в выпуске: 4 (32), 2020 года.

Бесплатный доступ

К настоящему времени коронавирусная болезнь, вызывающая острый респираторный синдром, выявлена почти во всех странах. Глобальное распространение вируса (SARS-CoV-2) стало пандемией, и не существует эффективной и утвержденной терапии против COVID-19. Ввиду чрезвычайной ситуации большинство потенциальных лекарственных средств для лечения COVID-19 допускаются к использованию пока на основании информации о безопасности и эффективности против SARS-CoV. Сейчас только лопинавир / ритонавир и ремдесивир являются единственными противовирусными препаратами, включенными в серьезные менеджмент-протоколы лечения COVID-19, а приемлемой альтернативой, возможно, является комбинированная терапия гидроксихлорохином с азитромицином. В сложившейся ситуации в качестве возможных методов лечения COVID-19 с учетом имеющихся знаний о патофизиологии инфекции стали предлагаться многие лекарственные вещества, обычно используемые в терапии других заболеваний. На основании известной в настоящее время информации в области путей вхождения в клетки вируса SARS-CoV-2, патофизиологических аспектов развития «цитокинового шторма» осуществлен обзор использования при COVID-19 противовирусных препаратов, противовоспалительных и иммуносупрессивных средств, витаминов и микроэлементов, которые сейчас широко применяются для лечения и профилактики различных заболеваний. Большинство испытуемых лекарственных средств, а также препараты цинка, витамины С и D3 обладали, наряду с иммуномодулирующим, еще и противовоспалительными свойствами или блокировали пути вхождения в клетки, или нарушали процесс внутриклеточной репликации вируса SARS-CoV. Извлекая уроки предыдущего опыта по преодолению SARS и MERS, в клинической практике для лечения COVID-19 использовалась серия существующих лекарств, а клинические испытания, оценивающие их эффективность и безопасность при COVID-19, продолжаются. Хотя предложено много видов лечения, для определения наиболее подходящих из них необходимо проводить специально спланированные рандомизированные клинические триалы, основанные на принципах доказательной медицины.

Еще

Коронавирус, противовирусные препараты, иммуномодулирующие препараты, противовоспалительные препараты, лекарственные препараты, клинические испытания

Короткий адрес: https://sciup.org/142226402

IDR: 142226402   |   DOI: 10.21668/health.risk/2020.4.19

Список литературы COVID-19: известные препараты, новые возможности

  • Coronavirus disease 2019 (COVID-19): current status and future perspectives / H. Li, S.-M. Liu, X.-H. Yu, C.-K. Tang // International Journal of Antimicrobial Agents. - 2020. - Vol. 55, № 5. - P. 105951. DOI: 10.1016/j.ijantimicag.2020.105951
  • Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV / J.S. Morse, T. Lalonde, S. Xu, W.R. Liu // Chembiochem. - 2020. - Vol. 21, № 5. - P. 730-738. DOI: 10.1002/cbic.202000047
  • A novel coronavirus from patients with pneumonia in China, 2019 / N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang [et al.] // N. Engl. J. Med. - 2020. - Vol. 382, № 8. - P. 727-733. DOI: 10.1056/NEJMoa2001017
  • Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin / P. Zhou, X. Yang, X. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu [et al.] // BioRxiv. - 2020. - № 23. - P. 18. DOI: 10.1038/s41586-020-2012-7
  • Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis // J. Med. Virol. - 2020. - Vol. 92, № 4. - P. 418-423. DOI: 10.1002/jmv.25681
  • The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells / M. Hoffmann, H. Kleine-Weber, N. Krüger, M. Müller, C. Drosten, S. Pöhlmann // bioRxiv. - 2020. - № 31. - P. 23.
  • DOI: 10.1101/2020.01.31.929042
  • Identification of potential cross-protective epitope between 2019-nCoV and SARS virus / T. Qiu, T. Mao, Y. Wang, M. Zhou, J. Qiu, J. Wang, J. Xu, Z. Cao // J. Genet. Genom. - 2020. - Vol. 20, № 47 (2). - P. 115-117.
  • DOI: 10.1016/j.jgg.2020.01.003
  • The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 Journal of Autoimmunity / C. Perricone, P. Triggianese, E. Bartoloni, G. Cafaro, A.F. Bonifacio, R. Bursi, R. Perricone, R. Gerli // Journal of Autoimmunity. - 2020. - Vol. 111. - P. 102468. 10.1016/ j.jaut.2020.102468
  • DOI: 10.1016/j.jaut.2020.102468
  • The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China / W. Zhang, Y. Zhao, F. Zhang, Q. Wang, T. Li, Z. Liu, J. Wang, Y. Qin [et al.] // Clinical Immunology. - 2020. - № 214. - P. 108393.
  • DOI: 10.1016/j.clim.2020.108393
  • COVID-19 infection and rheumatoid arthritis: Faraway, so close! / E.G. Favallia, F. Ingegnoli, O. De Lucia, G. Cincinelli, R. Cima, R. Caporali // Autoimmunity Reviews. - 2020. - Vol. 19, № 5. - P. 102523.
  • DOI: 10.1016/j.autrev.2020.102523
  • Castriotta Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019 / Y.-J. Geng, Z.-Y. Wei, H.-Y. Qian, J. Huang, R. Lodato, R.J. Castriotta [et al.] // Cardiovascular Pathology. - 2020. - № 47. - P. 107228. 10.1016/j.carpath. 2020.107228
  • DOI: 10.1016/j.carpath.2020.107228
  • COVID-19: consider cytokine storm syndromes and immunosuppression / P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, HLH Across Speciality Collaboration // Lancet. - 2020. - Vol. 28, № 395 (10229). - P. 1033-1034. 10.1016/S0140-6736 (20) 30628-0
  • DOI: 10.1016/S0140-6736(20)30628-0
  • Pedersen S.F., Ho Y.C. SARS-CoV-2: a storm is raging // J. Clin. Invest. - 2020. - Vol. 1, № 130 (5). - P. 2202-2205.
  • DOI: 10.1172/JCI137647
  • Coronavirus infections and immune responses / G. Li, Y. Fan, Y. Lai, T. Han, Z. Li, P. Zhou, P. Pan, W. Wang [et al.] // J. Med. Virol. - 2020. - Vol. 92, № 4. - P. 424-432.
  • DOI: 10.1002/jmv.25685
  • Coronaviruses - drug discovery and therapeutic options / A. Zumla, J.F. Chan, E.I. Azhar, D.S.C. Hui, K.-Y. Yuen // Nat. Rev. Drug. Discov. - 2016. - Vol. 15, № 5. - P. 327-347.
  • DOI: 10.1038/nrd.2015.37
  • Martinez M.A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus // Antimicrob Agents Chemother. - 2020. - Vol. 64, № 5. - P. 7.
  • DOI: 10.1128/AAC.00399-20
  • Elfiky A.A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study // Life Sci. - 2020. - Vol. 15, № 253. - P. 117592.
  • DOI: 10.1016/j.lfs.2020.117592
  • Potential antiviral therapeutics for 2019 Novel Coronavirus / H. Li, Y.M. Wang, J.Y. Xu, B. Cao // Chin. J. Tuberc. Respir. Dis. - 2020. - Vol. 5, № 43 (0). - P. E002.
  • DOI: 10.3760/cma.j.issn.1001-0939.2020.0002
  • Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China / D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang [et al.] // JAMA. - 2020. - Vol. 17, № 323 (11). - P. 1061-1069.
  • DOI: 10.1001/jama.2020.1585
  • Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial / Y.M. Arabi, A.Y. Asiri, A.M. Assiri, H.A.A. Jokhdar, A. Alothman, H.H. Balkhy, S. Aljohani, S. Al Harbi [et al.] // Trials. - 2020. - Vol. 3, № 21 (1). - P. 8.
  • DOI: 10.1186/s13063-019-3846-x
  • Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR / J. Lim, S. Jeon, H.Y. Shin, M.J. Kim, Y.M. Seong, W.J. Lee, K.W. Choe, Y.M. Kang, B. Lee, S.J. Park // J. Korean Med. Sci. - 2020. - Vol. 17, № 35 (6). - P. e79.
  • DOI: 10.3346/jkms.2020.35.e79
  • Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro / M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao // Cell. Res. - 2020. - Vol. 30, № 3. - P. 269-271.
  • DOI: 10.1038/s41422-020-0282-0
  • Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections // Antivir Chem. Chemother. - 2018. - Vol. 26. - P. 1631083325.
  • Cao Yu-C., Deng Q.-X., Dai S.-X. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence // Travel Medicine and Infectious Disease. - 2020. - Vol. 35. - P. 101647.
  • DOI: 10.1016/j.tmaid.2020.101647
  • Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) // Drug discoveries & therapeutics. - 2020. - Vol. 14, № 1. - Vol. 58-60.
  • DOI: 10.5582/ddt.2020.01012
  • Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 // Life Sciences. - 2020. - Vol. 1, № 248. - P. 117477.
  • DOI: 10.1016/j.lfs.2020.117477
  • Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures / R.A. Khamitov, S. Loginova, V.N. Shchukina, S.V. Borisevich, V.A. Maksimov, A.M. Shuster // Vopr Virusol. - 2008. - Vol. 53, № 4. - P. 9-13.
  • Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment / Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang // Biosci Trends. - 2020. - Vol. 16, № 14 (1). - P. 64-68.
  • DOI: 10.5582/bst.2020.01030
  • Harrison C. Coronavirus puts drug repurposing on the fast track // Nature biotechnology. - 2020. - Vol. 38, № 4. - P. 389-381.
  • DOI: 10.1038/d41587-020-00003-1
  • Chan K.W., Wong V.T., Tang S.C.W. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease // Am. J. Chin. Med. - 2020. - Vol. 48, № 3. - P. 737-762.
  • DOI: 10.1142/S0192415X20500378
  • Update of the EULAR recommendations for the management of large vessel vasculitis / B. Hellmich, A. Agueda, S. Monti, F. Buttgereit, H. de Boysson, E. Brouwer, R. Cassie, M.C. Cid [et al.] // Ann. Rheum. Dis. - 2020. - Vol. 79, № 1. - P. 19-30.
  • DOI: 10.1136/annrheumdis-2019-215672
  • Update of the EULAR recommendations for the management of systemic lupus erythematosus / A. Fanouriakis, M. Kostopoulou, A. Alunno, M. Aringer, I. Bajema, J.N. Boletis, R. Cervera, A. Doria [et al.] // Ann. Rheum. Dis. - 2019. - Vol. 78, № 6. - P. 736-745.
  • DOI: 10.1136/annrheumdis-2019-215089
  • Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) // Centers for Disease Control and Prevention. - 2020. - P. 13.
  • Shukla A.M., Shukla А.W. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues // Drugs. Context. - 2019. - Vol. 25, № 8. - P. 12.
  • DOI: 10.7573/dic.2019-9-1
  • Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 / P. Colson, J.-M. Rolain, J.-C. Lagier, P. Brouqui, D. Raoult // Int. J. Antimicrob. - 2020. - Vol. 55, № 4. - P. 105932.
  • DOI: 10.1016/j.ijantimicag.2020.105932
  • Chloroquine is a potent inhibitor of SARS coronavirus infection and spread / M.J. Vincent, E. Bergeron, S. Benjannet, B.R. Erickson, P.E. Rollin, T.G. Ksiazek, N.G. Seidah, S.T. Nichol // Virol. J. - 2005. - № 2. - P. 69.
  • DOI: 10.1186/1743-422X-2-69
  • Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia / Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia // Zhonghua Jie He He Hu Xi Za Zhi. - 2020. - Vol. 20, № 43. - P. E019.
  • Vademecum per la cura delle persone con malattia da COVID-19 - versione 2.0 2020. - SIMIT Societa Italiana di Malattie Infettive e Tropicali Sezione regione Lombardia, 2020. - P. 2.
  • Touret F., de Lamballerie X. Of chloroquine and COVID-19 // Antiviral. Res. - 2020. - № 177. - P. 104762.
  • DOI: 10.1016/j.antiviral.2020.104762
  • A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 / A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav // J. Crit. Care. - 2020. - № 57. - P. 279-283.
  • DOI: 10.1016/j.jcrc.2020.03.005
  • Melles R.B., Marmor M.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy // JAMA Ophthalmol. - 2014. - Vol. 132, № 12. - P. 1453-1460.
  • DOI: 10.1001/jamaophthalmol.2014.3459
  • Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis / P. Sarma, H. Kaur, H. Kumar, D. Mahendru, P. Avti, A. Bhattacharyya, M. Prajapat, N. Shekhar [et al.] // J. Med. Virol. - 2020. - Vol. 92, № 7. - P. 776-785.
  • DOI: 10.1002/jmv.25898
  • Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial / P. Gautret, J. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon [et al.] // Int. J. Antimicrob. Agents. - 2020. - Vol. 56, № 1. - P. 105949.
  • DOI: 10.1016/j.ijantimicag.2020.105949
  • From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus / S. Dilly, A. Fotso Fotso, N. Lejal, G. Zedda, M. Chebbo, F. Rahman, S. Companys, H.C. Bertrand [et al.] // J. Med. Chem. - 2018. - Vol. 61, № 16. - P. 7202-7217.
  • DOI: 10.1021/acs.jmedchem.8b00557
  • Ibuprofen attenuates cardiac fibrosis in Streptozotocin-induced diabetic rats / W. Qiao, C. Wang, B. Chen, F. Zhang, Y. Liu, Q. Lu, H. Guo, C. Yan [et al.] // Cardiology. - 2015. - Vol. 131, № 2. - P. 97-106.
  • DOI: 10.1159/000375362
  • Adnet F., Clama Schwok A. Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (ENACOVID) [Электронный ресурс] // ClinicalTrials.gov. - URL: https://clinicaltrials.gov/ct2/show/NCT04325633 (дата обращения: 12.05.2020).
  • Little P. Non-steroidal anti-inflammatory drugs and COVID-19 // BMJ. - 2020. - № 27. - P. 368: m1185.
  • DOI: 10.1136/bmj.m1185
  • Kotch C., Barrett D., Teachey D.T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome // Expert review of clinical immunology. - 2019. - Vol. 15, № 8. - P. 813-822.
  • DOI: 10.1080/1744666X.2019.1629904
  • Baricitinib as potential treatment for 2019-nCoV acute respiratory disease / P. Richardson, I. Griffin, C. Tucker, D. Smith, O. Oechsle, A. Phelan, M. Rawling, E. Savory, J. Stebbing // Lancet. - 2020. - Vol. 395, № 10223. - P. e30-e31. 10.1016/S0140-6736 (20) 30304-4
  • DOI: 10.1016/S0140-6736(20)30304-4
  • Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells / S. Matsuyama, N. Nao, K. Shirato, M. Kawase, S. Saito, I. Takayama, N. Nagata, T. Sekizuka [et al.] // Proceedings of the National Academy of Sciences. - 2020. - Vol. 31, № 117 (13). - P. 7001-7003.
  • DOI: 10.1073/pnas.2002589117
  • A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing / D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, M.J. O'Meara, J.Z. Guo, D.L. Swaney [et al.] // BioRxiv. - 2020. - Vol. 27. - P. 45.
  • DOI: 10.1101/2020.03.22.002386
  • Farouka A., Salmanb S. Dapsone and doxycycline could be potential treatment modalities for COVID-19 // Medical Hypotheses. - 2020. - № 140. - P. 109768.
  • DOI: 10.1016/j.mehy.2020.109768
  • Altschulera Е.L., Kast R.E. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) // Medical Hypotheses. - 2020. - № 141. - P. 109774.
  • DOI: 10.1016/j.mehy.2020.109774
  • Zhang L., Liu Y. Potential interventions for novel coronavirus in China: a systematic review // Journal of medical virology. - 2020. - Vol. 92, № 5. - P. 479-490.
  • DOI: 10.1002/jmv.25707
  • Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths / W.B. Grant, H. Lahore, S.L. McDonnell, C.A. Baggerly, C.B. French, J.L. Aliano, H.P. Bhattoa // Nutrients. - 2020. - Vol. 12, № 4. - P. E988.
  • DOI: 10.3390/nu12040988
  • Aranow C. Vitamin D and the immune system // J. Investig. Med. - 2011. - Vol. 59, № 6. - P. 881-886. DOI: 10.231/JIM.0b013e31821b8755
  • Nair R., Maseeh A. Vitamin D. The "sunshine" vitamin // J. Pharmacol. Pharmacother. - 2012. - Vol. 3, № 2. - P. 118-126.
  • DOI: 10.4103/0976-500X.95506
  • Kennel K.A., Drake M.T., Hurley D.L. Vitamin D deficiency in adults: when to test and how to treat // Mayo Clin. Proc. - 2010. - Vol. 85, № 8. - P. 752-757.
  • DOI: 10.4065/mcp.2010.0138
  • Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves / B. Nonnecke, J. McGill, J. Ridpath, R.E. Sacco, J.D. Lippolis, T.A. Reinhardt // Journal of dairy science. - 2014. - Vol. 97, № 9. - P. 5566-5579.
  • DOI: 10.3168/jds.2014-8293
  • Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data / A.R. Martineau, D.A. Jolliffe, R.L. Hooper, L. Greenberg, J.F. Aloia, P. Bergman, G. Dubnov-Raz, S. Esposito [et al.] // BMJ. - 2017. - Vol. 15, № 356. - P. i6583.
  • DOI: 10.1136/bmj.i6583
  • Wimalawansa S.J. Reducing Risks from COVID-19: Cost-Effective Ways of Strengthening Individual's and the Population Immunity with Vitamin D // J. Endocrinol. Sci. - 2020. - Vol. 2, № 2. - P. 5-13.
  • Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study / J.R. Lechien, C.M. Chiesa-Estomba, D.R. De Siati, M. Horoi, S.D. Le Bon, A. Rodriguez, D. Dequanter, S. Blecic [et al.] // Eur. Arch. Otorhinolaryngol. - 2020. - Vol. 277, № 8. - P. 2251-2261.
  • DOI: 10.1007/s00405-020-05965-1
  • Doty R.L. Treatment for smell and taste disorders: a critical review // Handb. Clin. Neurol. - 2019. - № 164. - P. 455-479.
  • DOI: 10.1016/B978-0-444-63855-7.00025-3
  • Li H., Liu S.-M., Yu X.-H., Tang C.-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents, 2020, vol. 55, no. 5, pp. 105951.
  • DOI: 10.1016/j.ijantimicag.2020.105951
  • Morse J.S., Lalonde T., Xu S., Liu W.R. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem, 2020, vol. 21, no. 5, pp. 730-738.
  • DOI: 10.1002/cbic.202000047
  • Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B. [et al.]. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, vol. 382, no. 8, pp. 727-733.
  • DOI: 10.1056/NEJMoa2001017
  • Zhou P., Yang X., Wang X., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y. [et al.]. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv, 2020, no. 23, pp. 18.
  • DOI: 10.1038/s41586-020-2012-7
  • Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol., 2020, vol. 92, no. 4, pp. 418-423.
  • DOI: 10.1002/jmv.25681
  • Hoffmann M., Kleine-Weber H., Krüger N., Müller M., Drosten C., Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, 2020, no. 31, pp. 23.
  • DOI: 10.1101/2020.01.31.929042
  • Qiu T., Mao T., Wang Y., Zhou M., Qiu J., Wang J., Xu J., Cao Z. Identification of potential cross-protective epitope between 2019-nCoV and SARS virus. J. Genet. Genom., 2020, vol. 20, no. 47 (2), pp. 115-117.
  • DOI: 10.1016/j.jgg.2020.01.003
  • Perricone C., Triggianese P., Bartoloni E., Cafaro G., Bonifacio A.F., Bursi R., Perricone R., Gerli R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 Journal of Autoimmunity. Journal of Autoimmunity, 2020, vol. 111, pp. 102468.
  • DOI: 10.1016/j.jaut.2020.102468
  • Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z., Wang J., Qin Y. [et al.]. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology, 2020, no. 214, pp. 108393.
  • DOI: 10.1016/j.clim.2020.108393
  • Favallia E.G., Ingegnoli F., De Lucia O., Cincinelli G., Cima R., Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmunity Reviews, 2020, vol. 19, no. 5, pp. 102523.
  • DOI: 10.1016/j.autrev.2020.102523
  • Geng Y.-J., Wei Z.-Y., Qian H.-Y., Huang J., Lodato R., Castriotta R.J. [et al.]. Castriotta Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019. Cardiovascular Pathology, 2020, no. 47, pp. 107228.
  • DOI: 10.1016/j.carpath.2020.107228
  • Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., HLH Across Speciality Collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 28, no. 395 (10229), pp. 1033-1034. 10.1016/S0140-6736 (20) 30628-0
  • DOI: 10.1016/S0140-6736(20)30628-0
  • Pedersen S.F., Ho Y.C. SARS-CoV-2: a storm is raging. J. Clin. Invest, 2020, vol. 1, no. 130 (5), pp. 2202-2205.
  • DOI: 10.1172/JCI137647
  • Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W. [et al.]. Coronavirus infections and immune responses. J. Med. Virol, 2020, vol. 92, no. 4, pp. 424-432.
  • DOI: 10.1002/jmv.25685
  • Zumla A., Chan J.F., Azhar E.I., Hui D.S.C., Yuen K.-Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev. Drug. Discov., 2016, vol. 15, no. 5, pp. 327-347.
  • DOI: 10.1038/nrd.2015.37
  • Martinez M.A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother, 2020, vol. 64, no. 5, pp. 7.
  • DOI: 10.1128/AAC.00399-20
  • Elfiky A.A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci., 2020, vol. 15, no. 253, pp. 117592.
  • DOI: 10.1016/j.lfs.2020.117592
  • Li H., Wang Y.M., Xu J.Y., Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin. J. Tuberc. Respir. Dis., 2020, vol. 5, no. 43 (0), pp. E002.
  • DOI: 10.3760/cma.j.issn.1001-0939.2020.0002
  • Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H. [et al.]. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, vol. 17, no. 323 (11), pp. 1061-1069. https: //10.1001/JAMA.2020. 1585
  • DOI: 10.1001/jama.2020.1585
  • Arabi Y.M., Asiri A.Y., Assiri A.M., Jokhdar H.A.A., Alothman A., Balkhy H.H., Aljohani S., Al Harbi S. [et al.]. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials, 2020, vol. 3, no. 21 (1), pp. 8.
  • DOI: 10.1186/s13063-019-3846-x
  • Lim J., Jeon S., Shin H.Y., Kim M.J., Seong Y.M., Lee W.J., Choe K.W., Kang Y.M., Lee B., S.J. Park Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean. Med. Sci., 2020, vol. 17, no. 35 (6), pp. e79.
  • DOI: 10.3346/jkms.2020.35.e79
  • Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell. Res., 2020, vol. 30, no. 3, pp. 269-271.
  • DOI: 10.1038/s41422-020-0282-0
  • Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir. Chem. Chemother., 2018, vol. 26, pp. 1631083325.
  • Cao Yu-C., Deng Q.-X., Dai S.-X. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease, 2020, vol. 35, pp. 101647.
  • DOI: 10.1016/j.tmaid.2020.101647
  • Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 2020, vol. 14, no. 1, vol. 58-60.
  • DOI: 10.5582/ddt.2020.01012
  • Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, 2020, vol. 1, no. 248, pp. 117477.
  • DOI: 10.1016/j.lfs.2020.117477
  • Khamitov R.A., Loginova S., Shchukina V.N., Borisevich S.V., Maksimov V.A., Shuster A.M. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr. Virusol., 2008, vol. 53, no. 4, pp. 9-13.
  • Wang Z., Chen X., Lu Y., Chen F., Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci. Trends., 2020, vol. 16, no. 14 (1), pp. 64-68.
  • DOI: 10.5582/bst.2020.01030
  • Harrison C. Coronavirus puts drug repurposing on the fast track. Nature biotechnology, 2020, vol. 38, no. 4, pp. 389-381.
  • DOI: 10.1038/d41587-020-00003-1
  • Chan K.W., Wong V.T., Tang S.C.W. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am. J. Chin. Med., 2020, vol. 48, no. 3, pp. 737-762.
  • DOI: 10.1142/S0192415X20500378
  • Hellmich B., Agueda A., Monti S., Buttgereit F., de Boysson H., Brouwer E., Cassie R., Cid M.C. [et al.]. Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis., 2020, vol. 79, no. 1, pp. 19-30.
  • DOI: 10.1136/annrheumdis-2019-215672
  • Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Cervera R., Doria A. [et al.]. Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis., 2019, vol. 78, no. 6, pp. 736-745.
  • DOI: 10.1136/annrheumdis-2019-215089
  • Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Centers for Disease Control and Prevention, 2020, pp. 13.
  • Shukla A.M., Shukla А.W. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context., 2019, vol. 25, no. 8, pp. 12.
  • DOI: 10.7573/dic.2019-9-1
  • Colson P., Rolain J.-M., Lagier J.-C., Brouqui P., Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob, 2020, vol. 55, no. 4, pp. 105932.
  • DOI: 10.1016/j.ijantimicag.2020.105932
  • Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., Seidah N.G., Nichol S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, no. 2, pp. 69.
  • DOI: 10.1186/1743-422X-2-69
  • Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 2020, vol. 20, no. 43, pp. E019.
  • Vademecum per la cura delle persone con malattia da COVID-19 - versione 2.0 2020. SIMIT Societa Italiana di Malattie Infettive e Tropicali Sezione regione Lombardia, 2020, 2 p.
  • Touret F., de Lamballerie X. Of chloroquine and COVID-19. Antiviral. Res., 2020, no. 177, pp. 104762.
  • DOI: 10.1016/j.antiviral.2020.104762
  • Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care., 2020, no. 57, pp. 279-283.
  • DOI: 10.1016/j.jcrc.2020.03.005
  • Melles R.B., Marmor M.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol, 2014, vol. 132, no. 12, pp. 1453-1460.
  • DOI: 10.1001/jamaophthalmol.2014.3459
  • Sarma P., Kaur H., Kumar H., Mahendru D., Avti P., Bhattacharyya A., Prajapat M., Shekhar N. [et al.]. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J. Med. Virol., 2020, vol. 92, no. 7, pp. 776-785.
  • DOI: 10.1002/jmv.25898
  • Gautret P., Lagier J., Parola P., Hoang V.T., Meddeb L., Mailhe M., Doudier B., Courjon J. [et al.]. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, vol. 56, no. 1, pp. 105949.
  • DOI: 10.1016/j.ijantimicag.2020.105949
  • Dilly S., Fotso Fotso A., Lejal N., Zedda G., Chebbo M., Rahman F., Companys S., Bertrand H.C. [et al.]. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J. Med. Chem., 2018, vol. 61, no. 16, pp. 7202-7217.
  • DOI: 10.1021/acs.jmedchem.8b00557
  • Qiao W., Wang C., Chen B., Zhang F., Liu Y., Lu Q., Guo H., Yan C. [et al.]. Ibuprofen attenuates cardiac fibrosis in Streptozotocin-induced diabetic rats. Cardiology, 2015, vol. 131, no. 2, pp. 97-106.
  • DOI: 10.1159/000375362
  • Adnet F., Clama Schwok A. Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (ENACOVID). ClinicalTrials.gov. Available at: https: //clinicaltrials.gov/ct2/show/NCT04325633 (12.05.2020).
  • Little P. Non-steroidal anti-inflammatory drugs and COVID-19. BMJ, 2020, no. 27, pp. 368: m1185.
  • DOI: 10.1136/bmj.m1185
  • Kotch C., Barrett D., Teachey D.T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert review of clinical immunology, 2019, vol. 15, no. 8, pp. 813-822.
  • DOI: 10.1080/1744666X.2019.1629904
  • Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A., Rawling M., Savory E., Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 2020, vol. 395, no. 10223, pp. e30-e31. 10.1016/S0140-6736 (20) 30304-4
  • DOI: 10.1016/S0140-6736(20)30304-4
  • Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T. [et al.]. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proceedings of the National Academy of Sciences, 2020, vol. 31, no. 117 (13), pp. 7001-7003.
  • DOI: 10.1073/pnas.2002589117
  • Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., O'Meara M.J., Guo J.Z., Swaney D.L. [et al.]. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. BioRxiv, 2020, vol. 27, pp. 45.
  • DOI: 10.1101/2020.03.22.002386
  • Farouka A., Salmanb S. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Medical Hypotheses, 2020, no. 140, pp. 109768.
  • DOI: 10.1016/j.mehy.2020.109768
  • Altschulera Е.L., Kast R.E. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS). Medical Hypotheses, 2020, no. 141, pp. 109774.
  • DOI: 10.1016/j.mehy.2020.109774
  • Zhang L., Liu Y. Potential interventions for novel coronavirus in China: a systematic review. Journal of medical virology, 2020, vol. 92, no. 5, pp. 479-490.
  • DOI: 10.1002/jmv.25707
  • http://refhub.elsevier.com/S0889-1591(20)30589-4/h0330Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L., Bhattoa H.P. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients, 2020, vol. 12, no. 4, pp. E988.
  • DOI: 10.3390/nu12040988
  • Aranow C. Vitamin D and the immune system. J. Investig. Med., 2011, vol. 59, no. 6, pp. 881-886. DOI: 10.231/JIM.0b013e31821b8755
  • Nair R., Maseeh A. Vitamin D. The "sunshine" vitamin. J. Pharmacol Pharmacother, 2012, vol. 3, no. 2, pp. 118-126.
  • DOI: 10.4103/0976-500X.95506
  • Kennel K.A., Drake M.T., Hurley D.L. Vitamin D deficiency in adults: when to test and how to treat. Mayo. Clin. Proc., 2010, vol. 85, no. 8, pp. 752-757.
  • DOI: 10.4065/mcp.2010.0138
  • Nonnecke B., McGill J., Ridpath J., Sacco R.E., Lippolis J.D., Reinhardt T.A. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. Journal of dairy science, 2014, vol. 97, no. 9, pp. 5566-5579.
  • DOI: 10.3168/jds.2014-8293
  • Martineau A.R., Jolliffe D.A., Hooper R.L., Greenberg L., Aloia J.F., Bergman P., Dubnov-Raz G., Esposito S. [et al.]. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ, 2017, vol. 15, no. 356, pp. i6583.
  • DOI: 10.1136/bmj.i6583
  • Wimalawansa S.J. Reducing Risks from COVID-19: Cost-Effective Ways of Strengthening Individual's and the Population Immunity with Vitamin D. J. Endocrinol. Sci., 2020, vol. 2, no. 2, pp. 5-13.
  • Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., Horoi M., Le Bon S.D., Rodriguez A., Dequanter D., Blecic S. [et al.]. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol, 2020, vol. 277, no. 8, pp. 2251-2261.
  • DOI: 10.1007/s00405-020-05965-1
  • Doty R.L. Treatment for smell and taste disorders: a critical review. Handb. Clin. Neurol, 2019, no. 164, pp. 455-479.
  • DOI: 10.1016/B978-0-444-63855-7.00025-3
Еще
Статья обзорная
SciUp 2024 © 2024 ©